Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Stoke Therapeutics Inc. (STOK) stock has reached a new 52-week high, hitting 20.5 USD. This milestone marks a significant upward trend for the company, which has seen its stock price climb by 38.44% over the past year. The biotech firm, now valued at $1.12 billion, has demonstrated remarkable growth with revenue surging over 1,200% in the latest reporting period. According to InvestingPro data, the stock maintains a healthy P/E ratio of 22.26 and an impressive current ratio of 6.98. The biotech firm’s positive momentum reflects growing investor confidence and interest in its innovative therapeutic solutions. As the company continues to advance its pipeline, stakeholders are closely watching its performance and potential for further growth in the competitive biotech sector. InvestingPro analysis reveals strong analyst consensus with multiple positive earnings revisions, suggesting continued optimism about the company’s prospects. Discover 12 additional exclusive ProTips and comprehensive financial analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Stoke Therapeutics announced its Q2 2025 earnings, surpassing analyst expectations with a narrower-than-anticipated loss and stronger revenue figures. The company reported an EPS of -$0.40, exceeding the forecasted -$0.50, and revenue of $13.8 million, significantly higher than the expected $9.39 million. Additionally, Stoke Therapeutics, in collaboration with Biogen, revealed new clinical data for zorevunersen, showing durable seizure reduction and cognitive improvements in Dravet syndrome patients over a three-year period. This data will be presented at the 36th International Epilepsy Congress. BTIG adjusted its price target for Stoke Therapeutics to $28 from $29 while maintaining a Buy rating, based on the 36-month data for zorevunersen. The data indicated enhanced seizure reductions in the third year of treatment, particularly for patients who started with the planned 45 mg loading doses. These developments reflect ongoing advancements and investor interest in Stoke Therapeutics’ therapeutic efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.